

Completion of share consolidation

Melbourne, Australia; 16 January 2017: At the 28 December 2016 Extraordinary General Meeting (**EGM**) of the shareholders of Mach7 Technologies Limited (the **Company**), it was resolved that the Company's securities be consolidated through the conversion of every 10 ordinary shares, performance shares or options on issue as at the record date of 10 January 2017 into 1 ordinary share, performance share, or option, with fractions of a security being rounded to the nearest whole number, exact half securities being rounded up and post consolidation holdings of less than one being rounded up (**Consolidation**).

The Company advises that the Consolidation has been completed and the Company's quoted securities are now trading on a post-Consolidation basis. Following the Consolidation, the Company now has the following securities on issue:

1. 67,739,871 quoted, unrestricted fully paid ordinary shares
2. 339,850 quoted fully paid ordinary shares escrowed until 1 June 2017
3. 57,690 quoted fully paid ordinary shares escrowed until 1 July 2017
4. 5,874,817 unquoted fully paid ordinary shares escrowed until 18 February 2017
5. 44,193,300 unquoted fully paid ordinary shares escrowed until 8 April 2017
6. 1,143,261 unquoted, unrestricted performance shares (see the Explanatory Memorandum accompanying the Notice of the EGM, dated 28 November 2016, for further detail about the effect of the Consolidation on the vesting conditions of the various classes of performance shares)
 - 571,632 Class A
 - 190,543 Class B
 - 190,543 Class C
 - 190,543 Class D
7. 28,856,738 unquoted performance shares escrowed until 8 April 2017
 - 14,428,370 Class A
 - 4,809,456 Class B
 - 4,809,456 Class C
 - 4,809,456 Class D
8. 2,995,260 unquoted, unrestricted options exercisable at \$0.50 each, expiring 6 February 2017
9. 1,293,985 unquoted options exercisable at \$0.50 each, expiring 6 February 2017 and escrowed until 18 February 2017
10. 100,000 unquoted options exercisable at \$1.00 each, vesting on 8 April 2017 and expiring on 8 April 2020
11. 475,000 unquoted options exercisable at \$1.00 each, vesting on 8 April 2018 and expiring on 8 April 2021
12. 125,000 unquoted options exercisable at \$1.00 each, vesting on 9 December 2018 and expiring on 9 December 2021.

A consolidation notice will be forwarded to securityholders on 19 January 2017.

- ENDS

Contacts:

Jenni Pilcher	Alyn Tai
CEO Australia, CFO	Company Secretary
+61 3 9646 2222 (Australia)	+61 3 9286 7500 (Australia)
jenni.pilcher@mach7t.com	alyn.tai@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced [clinical viewing](#) and optimised [vendor neutral archiving](#) solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au